

Value IN HEALTH

VOLUME 17

NUMBER 8

DECEMBER 2014

TABLE OF CONTENTS

COMMENTARY

- 757** **Toward a Functional Definition of a “Rare Disease” for Regulatory Authorities and Funding Agencies**

Joe T.R. Clarke, Doug Coyle, Gerald Evans, Janet Martin, and Eric Winkquist

ORIGINAL ARTICLES***Economic Evaluation***

- 762** **Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results**

Becky Pennington and Sarah Davis

- 772** **Optimizing the Position and Use of Omalizumab for Severe Persistent Allergic Asthma Using Cost-Effectiveness Analysis**

Rita Faria, Claire McKenna, and Stephen Palmer

- 783** **Economic Evaluation of a Cluster Randomized Trial of Interventions to Improve Health Workers’ Practice in Diagnosing and Treating Uncomplicated Malaria in Cameroon**

Lindsay Mangham-Jefferies, Virginia Wiseman, Olivia A. Achonduh, Thomas L. Drake, Bonnie Cundill, Obinna Onwujekwe, and Wilfred Mbacham

- 792** **Cost-Effectiveness of Telaprevir in Patients with Genotype 1 Hepatitis C in Australia**

Emma Warren, Alison Wright, and Brandon Jones

- 801** **Cost-Effectiveness of Three Adjunct Cellular/Tissue-Derived Products Used in the Management of Chronic Venous Leg Ulcers**

Marissa J. Carter, Curtis Waycaster, Kathleen Schaum, and Adrienne M. Gilligan

Patient-Reported Outcomes

- 814** **Conceptual Model and Economic Experiments to Explain Nonpersistence and Enable Mechanism Designs Fostering Behavioral Change**

Behnud Mir Djawadi, René Fahr, and Florian Turk

- 823** **Validation of the Patient Perception of Intensity of Urgency Scale in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia**

Susan D. Mathias, Ross D. Crosby, Jameel Nazir, Monique Klaver, Ted Drogendijk, Zalmi Hakimi, and Isaac A. Odeyemi

Preference-Based Assessments

- 830** **Parents’ Willingness to Pay for Biologic Treatments in Juvenile Idiopathic Arthritis**

Heather F. Burnett, Wendy J. Ungar, Dean A. Regier, Brian M. Feldman, and Fiona A. Miller

- 838** **Valuations of Genetic Test Information for Treatable Conditions: The Case of Colorectal Cancer Screening**

Vikram Kilambi, F. Reed Johnson, Juan Marcos González, and Ateesha F. Mohamed

- 846** **US Valuation of Health Outcomes Measured Using the PROMIS-29**

Benjamin M. Craig, Bryce B. Reeve, Paul M. Brown, David Cella, Ron D. Hays, Joseph Lipscomb, A. Simon Pickard, and Dennis A. Revicki

TABLE OF CONTENTS - continued

Comparative Effectiveness Research/Health Technology Assessment (HTA)

854 Capitalizing on Prescribing Pattern Variation to Compare Medications for Type 2 Diabetes

Julia C. Prentice, Paul R. Conlin, Walid F. Gellad, David Edelman, Todd A. Lee, and Steven D. Pizer

SYSTEMATIC REVIEWS

863 Predicting Adherence to Medications Using Health Psychology Theories: A Systematic Review of 20 Years of Empirical Research

Emily A.F. Holmes, Dyfrig A. Hughes, and Valerie L. Morrison

877 Does Convenience Matter in Health Care Delivery? A Systematic Review of Convenience-Based Aspects of Process Utility

A. Higgins, J. Barnett, C. Meads, J. Singh, and L. Longworth

POLICY PERSPECTIVES

888 Evolution of Drug Reimbursement in Canada: The Pan-Canadian Pharmaceutical Alliance for New Drugs

Don Husereau, William Dempster, Adrienne Blanchard, and Johanne Chambers

LETTER TO THE EDITOR

895 Performance of the UKPDS Outcomes Model for Prediction of Myocardial Infarction and Stroke in the ADDITION-Europe Trial Cohort: Does the ADDITION Validation Add Up?

Alastair Gray, Rury Holman, Philip Clarke, and Jose Leal

896 Erratum

I Instructions for Authors